Search Bar & Filters
Found 76 Actively Recruiting clinical trials
Actively Recruiting
Non-small cell lung cancer NSCLC is a common type of lung cancer where abnormal cells grow quickly, affecting lung function. This study focuses on advanced stages of squamous and nonsquamous NSCLC that cannot be surgically removed or have spread to other body parts. Researchers are investigating TAK-928, a new drug designed to activate immune cells called T cells to better attack and destroy tumor cells, comparing it to the standard treatment, docetaxel, in adults with this condition. TAK-928 is a bispecific monoclonal antibody administered through intravenous infusion that targets specific immune pathways to stimulate T cells and natural killer cells against cancer. Participants will receive either TAK-928 or docetaxel, also given by IV infusion. Treatment may continue for up to 24 months, with duration depending on individual response and side effects. The trial includes a randomized, parallel design to evaluate the efficacy and safety of TAK-928 compared to docetaxel. Participants will visit the study clinic multiple times for assessments including imaging scans to measure tumor response, laboratory tests, and questionnaires about quality of life and symptoms. Researchers will monitor treatment effects, side effects, and survival outcomes for up to 26 months. Safety and immune response will also be tracked throughout the study, with ongoing evaluations until treatment ends. Participant involvement may last up to two years or more depending on individual circumstances.
Actively Recruiting
Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.
Actively Recruiting
The trial investigates treatments for adults with KRASNRAS and BRAF wild-type recurrent, unresectable, or metastatic colorectal cancer who have previously undergone chemotherapy. It compares how long participants live without disease progression and overall survival when treated with two different combinations of chemotherapy and targeted biological agents. This phase 3 study explores differences in outcomes between the use of amivantamab plus FOLFIRI chemotherapy and cetuximab or bevacizumab plus FOLFIRI chemotherapy. Participants are randomly assigned to one of two groups. One group receives amivantamab together with FOLFIRI, a chemotherapy regimen including 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan. The other group receives either cetuximab or bevacizumab with the same FOLFIRI chemotherapy. Treatments are given in 28-day cycles and continue until disease progression is observed on scans or other stopping criteria are met. During the study, participants undergo regular monitoring including radiographic scans to assess disease status and progression-free survival for up to 2 years and overall survival for over 4 years. Researchers also evaluate tumor response rates, duration and time to response, quality of life through questionnaires, side effects, and laboratory tests. The total study duration may extend up to more than 4 years to thoroughly assess treatment outcomes and safety.
Actively Recruiting
This clinical trial is designed to compare the duration participants remain free of disease progression when treated with two different combinations of therapies for adults with KRASNRAS and BRAF wild-type unresectable or metastatic left-sided colorectal cancer. The study focuses on how amivantamab combined with chemotherapy compares to cetuximab combined with chemotherapy in treating this specific cancer type. Participants will be divided into two groups. One group receives amivantamab combined with chemotherapy, either mFOLFOX6 containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and oxaliplatin or FOLFIRI containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan hydrochloride. The other group receives cetuximab combined with the same chemotherapy options. Treatments are given in 28-day cycles and continue until the cancer progresses or other reasons require stopping the treatment. Throughout the study, participants will undergo regular evaluations to monitor how long they remain without disease progression, assessed by independent review and investigators. Other assessments include overall survival, response rates, duration of response, quality of life questionnaires, and safety monitoring up to several years. The study spans several years, with primary outcomes measured up to over four years and additional follow-up extending beyond seven years to gather comprehensive data on treatment effects and patient well-being.
Actively Recruiting
Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tacabrutideg compared with investigators choice treatments in people with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with both Bruton Tyrosine Kinase inhibitors BTKi and B-cell LeukemiaLymphoma 2 protein inhibitors BCL2i. This study aims to compare how long participants live without their disease worsening under these treatments. The study is a Phase 3, randomized trial sponsored by BeOne Medicines. Participants will be randomly assigned to receive either tacabrutideg taken orally once daily until treatment discontinuation criteria are met, or investigators choice of treatment. The investigators choice includes combinations such as idelalisib plus rituximab for CLL only, bendamustine plus rituximab, or venetoclax plus rituximab retreatment. Some of these drugs are administered orally while others are given intravenously. During the study, participants will be closely monitored for progression-free survival over approximately 36 months, along with overall survival and response rates. Researchers will assess quality of life using specific questionnaires for up to 24 months, and track treatment-emergent adverse events. The study involves regular assessments and evaluations to understand treatment effects and safety over the course of participation, which may last several years until study completion in 2030.
Actively Recruiting
Researchers are evaluating intensity-modulated post-operative radiation therapy I-PORT combined with standard chemotherapy or immunotherapy versus standard therapy alone for patients with non-small cell lung cancer NSCLC who have remaining lymph node cancer after surgery. This phase II trial aims to determine if I-PORT improves disease-free survival and assesses its impact on severe late cardiopulmonary side effects compared to standard care. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy or immunotherapy alone, while the other undergoes I-PORT daily Monday through Friday over 5 to 6 weeks, starting 4 to 12 weeks after surgery, followed by standard therapy. Throughout the study, patients have CT andor MRI scans, FDG-PET scans, and blood samples collected. Treatment continues until disease progression or unacceptable side effects occur. After completing treatment, participants are followed every 3 months for 2 years and then every 6 months for an additional 3 years. The study measures disease-free survival up to 5 years, overall survival at 2 and 5 years, rates of local and distant cancer control, and patient-reported symptoms related to heart and lung health. Safety is closely monitored, focusing on acute and late side effects affecting the heart and lungs.
Actively Recruiting
Researchers are evaluating the safety and long-term effectiveness of the VARIPULSE Catheter System in treating persistent atrial fibrillation PsAF, a heart rhythm disease. The study focuses on patients undergoing catheter ablation procedures involving pulmonary vein isolation PVI and superior vena cava isolation SVCI, with some also receiving posterior wall isolation PWI. Additionally, it assesses safety for those having a simultaneous left atrial appendage occlusion LAAO procedure to reduce stroke risk. Participants will receive catheter ablation treatment using the VARIPULSE Catheter System, which includes a bi-directional catheter and generator delivering pulsed field ablation. Two groups are studied one undergoing PVI and SVCI, and another receiving PVI, SVCI plus PWI. Some participants in both groups may also have a concurrent LAAO procedure using commercially available devices. Follow-up for all participants extends up to 36 months after the procedures. Throughout the study, participants will be monitored for early adverse events within about 7 days post-procedure and for occurrences of atrial tachyarrhythmia from 2 to 6 months after treatment. Quality of life changes will be evaluated at 12 months using a specific atrial fibrillation questionnaire. Researchers will also track safety and effectiveness over 3 years through regular assessments, which may include clinical visits, tests, and questionnaires to measure heart rhythm stability and stroke risk reduction.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the VARIPULSE pulsed field ablation PFA catheter compared to the FDA-approved FARAWAVE PFA catheter in people with symptomatic persistent atrial fibrillation PsAF, a condition characterized by a continuous irregular and rapid heartbeat lasting more than 7 days and not stopping on its own. The study is a randomized controlled trial led by Biosense Webster, Inc., aiming to better understand these devices performance in treating PsAF. Participants with PsAF will undergo catheter ablation using either the VARIPULSE catheter or the FARAWAVE catheter. Some participants may join a magnetic resonance imaging MRI subset, undergoing MRI scans before and after the ablation procedure. After the procedure, participants will be followed for up to 12 months to monitor their health and treatment outcomes. During the study, participants will have assessments including MRI scans for those in the MRI subset, electrocardiograms, and symptom monitoring. Researchers will measure the occurrence of early adverse events within 7 days after the procedure and track the time until episodes of atrial tachyarrhythmia occur from Day 61 onward. Quality of life changes will also be assessed at baseline and six months after the procedure. Safety and effectiveness will be monitored throughout the 12-month follow-up period.
1-10 of 76
1